See more : Kirloskar Industries Limited (KIRLOSIND.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Vir Biotechnology, Inc. (VIR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vir Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- SWMBRD Sports Inc. (SWIM.CN) Income Statement Analysis – Financial Results
- Hecla Mining Company (0R0A.L) Income Statement Analysis – Financial Results
- Samart Corporation Public Company Limited (SAMART.BK) Income Statement Analysis – Financial Results
- Amica S.A. (AMC.WA) Income Statement Analysis – Financial Results
- Aquirian Limited (AQN.AX) Income Statement Analysis – Financial Results
Vir Biotechnology, Inc. (VIR)
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 86.18M | 1.58B | 1.09B | 67.25M | 711.00K | 868.00K | 149.00K |
| Cost of Revenue | 2.77M | 146.32M | 65.87M | 301.58M | 148.47M | 100.23M | 62.51M |
| Gross Profit | 83.42M | 1.43B | 1.02B | -234.33M | -147.76M | -99.36M | -62.36M |
| Gross Profit Ratio | 96.79% | 90.74% | 93.94% | -348.48% | -20,782.14% | -11,447.12% | -41,854.36% |
| Research & Development | 589.67M | 474.65M | 448.01M | 302.41M | 148.47M | 100.23M | 62.51M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 70.94M | 37.60M | 29.13M | 21.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 174.05M | 161.76M | 160.79M | 70.94M | 37.60M | 29.13M | 21.69M |
| Other Expenses | 0.00 | -35.33M | -8.35M | -9.12M | -7.38M | -212.00K | 83.00K |
| Operating Expenses | 767.72M | 601.09M | 600.45M | 364.23M | 178.69M | 119.56M | 81.65M |
| Cost & Expenses | 770.49M | 747.40M | 666.32M | 364.23M | 178.69M | 119.56M | 81.65M |
| Interest Income | 86.99M | 28.09M | 439.00K | 2.84M | 8.51M | 2.54M | 638.00K |
| Interest Expense | 0.00 | 183.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.45M | 15.49M | 11.98M | 8.81M | 4.52M | 2.76M | 432.00K |
| EBITDA | -664.85M | 833.07M | 420.75M | -289.80M | -173.46M | -115.94M | -81.07M |
| EBITDA Ratio | -771.47% | 59.74% | 26.01% | -441.64% | -25,032.21% | -13,356.68% | -54,406.04% |
| Operating Income | -684.31M | 833.07M | 276.89M | -296.98M | -177.98M | -118.69M | -81.50M |
| Operating Income Ratio | -794.04% | 52.71% | 25.47% | -441.64% | -25,032.21% | -13,674.19% | -54,695.97% |
| Total Other Income/Expenses | 56.11M | -78.79M | 129.05M | -1.63M | 3.45M | 2.33M | 721.00K |
| Income Before Tax | -628.19M | 754.28M | 549.80M | -298.61M | -174.53M | -116.36M | -80.78M |
| Income Before Tax Ratio | -728.93% | 47.72% | 50.58% | -444.06% | -24,546.98% | -13,405.99% | -54,212.08% |
| Income Tax Expense | -13.08M | 238.44M | 21.22M | 54.00K | 154.00K | -480.00K | -10.92M |
| Net Income | -615.06M | 515.84M | 528.58M | -298.67M | -174.68M | -115.88M | -69.85M |
| Net Income Ratio | -713.69% | 32.64% | 48.62% | -444.14% | -24,568.64% | -13,350.69% | -46,880.54% |
| EPS | -4.59 | 3.89 | 4.07 | -2.51 | -1.62 | -1.20 | -0.72 |
| EPS Diluted | -4.59 | 3.83 | 3.96 | -2.51 | -1.62 | -1.20 | -0.72 |
| Weighted Avg Shares Out | 134.13M | 132.61M | 129.88M | 119.16M | 107.65M | 96.91M | 96.91M |
| Weighted Avg Shares Out (Dil) | 134.13M | 134.81M | 133.44M | 119.16M | 107.65M | 96.91M | 96.91M |
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
Vir Biotechnology (VIR) Down on Influenza Study Failure
Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial
Why Shares of Vir Biotechnology Are Plunging Thursday
Vir Biotechnology says mid-stage trial of a flu treatment failed to meet main goals
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
Source: https://incomestatements.info
Category: Stock Reports